volitionrx close blood-bas diagnost colorect cancer
could help address critic gap screen complianc despit avail
effect method detect cancer earliest treatabl stage
approxim one three adult forgo recommend screen procedur
due non-invas natur believ volutionrx blood-bas diagnost
could improv screen complianc compani innov nu platform
gener compel earli data next month
transform compani conduct larg sampl
valid studi screen product support potenti eu commerci
launch initi coverag vrnx outperform rate pt
volitionrx diagnost platform detect epigenet modif associ
cancer compani identifi dozen distinct molecular signatur
term nu qs associ cancer focus nucleosom durabl
dna-protein complex releas circul blood cancer cell
die nu qs detect standard elisa enzyme-link immunosorb
assay panel sever nu qs use product
volitionrx priorit develop nu q-base screen diagnost
earli detect commonli use screen method either invas
colonoscopi reli collect fecal sampl cologuard contrast
nu q-base screen could perform part patient routin blood workup
base earli data gener multipl nu panel believ
perform compani diagnost could success commerci
valid larger studi believ compani nu screen
could receiv endors medic societi option non-compli
volitionrx aim final nu panel asymptomat screen
base result train set product must
valid larg sampl studi potenti allow volitionrx file
label claim launch eu us believ compani
would seek fda approv pma pathway
valuat volitionrx current center market opportun
screen non-compli adult includ subject us alon
howev nu q-base panel achiev perform level compar
non-invas screen option could potenti adopt
standard front-lin screen option greatli expand market opportun
volitionrx diagnost compani
focus develop blood
detect epigenet
signatur cancer
analyst certif import disclosur see disclosur
success valid studi support label eu
eu commerci launch
success edrn/nci valid studi us fda
approv us commerci launch
recommend medic societi uspstf
screen option non-compli subject
risk-adjust revenu approxim
higher anticip sale eu us non-
success commerci nu diagnost addit
nu adopt front-lin screen option elig adult
success product develop addit cancer
believ volit nu blood-bas diagnost
meaning improv gap screen complianc
colorect cancer valuat base primarili nu qs
market opportun screen us eu also
includ small contribut nu triag test select
potenti result screen sampl train studi
final nu panel use eu screen valid studi
potenti obtain ce mark launch eu
final nu panel us-focus screen valid studi
nu diagnost perform valid studi lower
failur obtain eu label claim and/or fda approv
support use non-compli subject
inabl nu obtain accept medic societi
guidelin uspstf limit commerci uptak
valu volit use averag revenu ep multipl analysi arriv price target appli multipl
risk-adjust revenu estim discount period appli multipl ep
estim discount period ad volit project cash per share round
obtain month price target
risk includ price clinic regulatori financ market competit
note view vnrx stock trade specul appropri risk-toler investor
volitionrx ltd multi-n biotechnolog compani base belgium focus
develop blood-bas diagnost earli detect cancer compani
innov screen platform identifi molecular signatur cancer present
circul nucleosom highli stabl complex dna histon protein
aberrantli modifi cancer cell compani develop distinct
antibody-bas test nucleosom marker term nu qs detect
standard elisa enzyme-link immunosorb assay methodolog optim
perform diagnost volitionrx combin sever nu qs along non-nu
base assay diagnost panel compani lead product diagnost screen
colorect cancer could readi commerci launch europ
reduc number unnecessari colonoscopi perform countri
nation screen program blood-bas nu diagnost could also deploy
triag set combin standard fecal immunochem test
screen volitionrx activ explor use nu qs indic includ
pancreat prostat lung cancer
initi coverag volit outperform rate price target
next month view volit gener compel earli data sever
nu panel perform maintain larger valid studi believ
compani could receiv favor label eu earli next year follow
fda approv us believ regulatori author would permiss
new product aim improv screen complianc exemplifi
fda approv epigenom blood-bas epi procolon despit mediocr
perform profil encourag earli data hand volitionrx first larg
valid studi sampl slate readout view compani
overlook innov cancer diagnost space believ investor
shown insati appetit blood-bas diagnost vividli illustr grail
financ track record includ seri
valuat volitionrx center nu qs market opportun among screen
non-compli adult us eu includ subject us
subject eu sale estim assum nu q-base screen
non-compli subject would back major medic societi includ
recommend statement us diagnost watchdog us prevent
servic task forc uspstf howev product valid studi demonstr
perform level compar non-invas screen option
cologuard could adopt standard front-lin screen option expand
address market subject us alon
valu volitionrx use discount earn per share revenu multipl
analysi current ascrib valu nu q-base product two colorect
cancer screen set front-lin screen non-compli us eu subject
triag set combin fecal-bas test select eu countri
also assum modest revenu stream sale research-us kit voltionrx
nu panel commerci partner activ motif believ
screen non-compli colorect cancer repres primari unmet medic
need address compani nu q-base product
given pre-commerci stage nu elect use high discount rate
risk-adjust anticip sale model po triag product
po non-triag set believ nu product could receiv
ce mark label claim eu front-lin triag
indic potenti us approv screen estim total
risk-adjust sale volitionrx basi year evalu
detail market model estim refer exhibit page
profit molecular diagnost compani
histor trade within averag sale multipl rang averag
ep multipl rang valu volit use revenu ep multipl
analysi appli multipl risk-adjust revenu estim
discount period obtain target price appli
multipl ep estim discount period
obtain target price averag result two method ad
project cash per share obtain month price target round
exhibit valuat sensit analysi
see upsid potenti volit sever avenu primarili nu q-base
screen demonstr perform par better current front-lin screen
approach plan valid studi believ test could gain broader
recommend screening-elig adult addit current model
product sale outsid eu us territori although manag indic
interest pursu commerci asia final includ success
develop commerci nu q-base diagnost symptomat
patient addit cancer type acknowledg platform could
util earli detect varieti differ malign
molecular diagnost develop inher riski invest thesi depend
volitionrx abil success develop manufactur commerci nu q-
base product date nu q-base diagnost valid larg
sampl studi directli compar perform fecal-bas screen
perform nu diagnost small sampl studi may
predict perform larg valid studi volitionrx may face delay
commerci due neg ambigu clinic result
volitionrx also face competit novel non-invas diagnost approach
includ circul tumor dna ctdna circul tumor cell ctc diagnost
exampl cellmax recent present earli perform result ctc-base
diagnost addit volitionrx may also face ip relat risk novel
diagnost deem infring issu patent competit product
major development-stag molecular diagnost compani volitionrx
abil maintain suffici fund critic advanc product
candid current volitionrx cash flow neg believ remain
nu asymptomat screen
potenti present result sampl train studi
potenti final nu panel use eu valid studi
potenti complet sampl valid studi support eu label
potenti obtain ce mark european launch
potenti final nu panel us-focus valid studi sampl
nu triag
potenti final nu triag product panel
potenti obtain ce mark eu launch
nu symptomat screen
final regulatori strategi approv label claim us eu
compani present oppenheim co estim
new-cleosom approach cancer
cancer second lead caus death world-wide earli diagnosi critic
long-term patient surviv malign often manag detect
earli stage progress spread throughout bodi metastas
howev cancer lack effect screen option mani case screen
option avail invas unpleas patient pap smear cervic
cancer colonoscopi colorect cancer case patient complianc present
major hurdl univers screen believ effect reliabl blood-bas
diagnost could repres much-need breakthrough cancer screen could
dramat improv earli detect rate volitionrx aim make blood base
diagnost realiti mani cancer novel nucleosome-bas diagnost
nu platform scout molecular signatur cancer focus nucleosom
blood nucleosom basic unit cell use packag dna due
compact structur persist circul long death cell
consist dna approxim base pair tightli wrap around complex small
protein call histon schemat illustr exhibit
nucleosom subject extens post-transl modif includ
phosphoryl acetyl methyl ubiquitin variou site
pattern histon modif influenc cell function metabol state
modif serv scaffold protein involv dna transcript
repair modif residu profound impact gene express
in-depth review histon modif cancer see spring harb
cancer cell prolifer accumul variou histon modif principl
make distinct healthi cell molecular signatur malign diseas
present nucleosom underpin volitionrx nu platform
importantli technolog entir distinct sequencing-bas diagnost
use identifi specif cancer-associ mutat detect tumor
biopsi sometim circul blood contrast sequencing-bas method
nucleosom agnost specif mutat patient dna reflect
aberr epigenet metabol state common cancer
exhibit structur nucleosom common modif
unfortun presenc specif histon modif necessarili indic
cancer presenc elev nucleosom circul blood
develop viabl diagnost volitionrx use panel nucleosome-bas marker
collect point presenc cancer date volit identifi differ
nu marker includ specif histon dna modif individu
nu qs low diagnost power evalu panel marker time
combin non-nucleosom biomark potenti compani
diagnost platform begin emerg
nu test depend antibodi specif desir nucleosom featur
quantifi use standard elisa methodolog elisa-bas assay
routin use medic diagnost often detect molecular signatur viral
bacteri infect approach illustr exhibit util antibodi
immobil nucleosom within standard microtit plate well label report
antibodi use quantifi nucleosom modif interest elisa extrem
sensit allow reliabl quantif minut amount target small
aliquot blood addit advantag includ eas use low oper
cost flexibl run virtual clinic set
exhibit elisa-bas detect nucleosom biomark
core cancer diseas caus mutat dna gene critic cell
homeostasi blood-bas cancer diagnost focus dna
mutat oppos epigenet modif histon field circul
tumor dna ctdna -base diagnost yield success stori view
main problem stem rel scarciti ctdna blood heterogen
cancer-associ mutat patient howev note ctdna shown
promis identif virally-driven cancer nasopharyng cancer
caus epstein-barr viru ebv cancer viral replic within dna
oncogen caus consist amplifi signatur ebv-dna cancer cell
engl nucleosom marker cancer like
preval cancer-associ mutat believ nu q-base diagnost could
offer better chanc success earli detect come non-vir
nu take aim
view excel indic area volitionrx priorit develop
diagnost current avail screen method clearli inadequ nearli
screen elig adult us around europ non-compli
recommend screen guidelin result second deadliest cancer
lung cancer volit look turn tide mortal improv
screen therebi detect cancer potenti effect
earli stage colorect cancer develop slowli diseas usual start benign
polyp transform higher risk adenoma lesion still consid
pre-cancer high-risk lesion invad epitheli mucosa
submucosa see exhibit consid cancer stage colorect
cancer stage i-iv delin progress invas tumor stage iv crc
advanc state metastas colon area bodi
importantli transit low-risk polyp high-risk adenoma full-blown
take ten year natur histori studi peg transform rate
small polyp high-risk polyp annual transform rate high-risk
polyp annual given low growth rate surpris
estim adult age polyp grade gastroenterolog
cancer precancer lesion identifi earli
remov colonoscopi greatli improv odd long-term cancer-fre surviv
exampl success remov stage cancer result cancer-fre surviv
cancer metastas surviv drop
approxim per nci view characterist make colorect cancer
ideal indic prevent screen
exhibit stage colorect cancer
call popul screen program
screen adult age eu similarli
recommend member state establish earli detect program
screen colonoscopi gold standard term screen perform
recommend everi ten year averag risk individu howev uspstf also
recogn mani peopl reluct undergo colonoscopi procedur
requir bowel prep usual perform gener anesthesia
effort expand screen broader popul recent uspstf
test detect presenc trace amount blood fecal sampl diagnos
develop sensit fecal-bas test call cologuard
fit-dna approv also includ recent uspstf
recommend addit measur blood fece cologuard includ ten
assay detect dna hallmark includ mutat common oncogen
kra summari recent uspstf recommend exhibit
despit effort improv population-bas screen us includ gener
stipend afford act provid implement
program patient adher program approxim
patient current recommend screen latest censu see
exhibit eu screen non-compli also remain persist hurdl despit
complianc vari across member state rang low-end
high-end world gastroenterol may member state
develop implement organ fit-screen program
success improv complianc scand gastroenterol jun
view approv cologuard us improv gap screen
complianc far pursu commerci cologuard
eu base cologuard perform rel uspstf endors use
three-year interv versu yearli interv requir
despit benefit see cologuard ideal solut address broad
need screen non-compli like use cologuard requir user willing
collect fecal sampl addit dna-bas assay cologuard requir specif
manipul fecal sampl sent back process center
view addit step may account less-than-stellar test return rate
recent report exact patient complianc cologuard screen
decemb mean test ship patient
exact properli complet return
believ blood-bas test could perform part patient
routin blood workup could improv screen complianc assumpt part
base larg survey-bas studi particip declin colonoscopi
germani studi particip claim would prefer blood-
base test avail compar prefer test bmc gastroenterol
oct separ studi prospect blood-bas diagnost
particip particip blood-bas arm complet test compar
arm cancer treatment research
opinion variou nu panel alreadi gener compel result sever
screen trial summar exhibit earli studi includ variou
combin nu panel encourag reproduc
data across trial asymptomat symptomat sampl set
exhibit nu panel perform earli screen studi
remind perform diagnost commonli measur term
sensit specif sensit measur probabl correctli identifi
true posit popul hand specif provid measur
diagnost would sensit specif
use simplifi exampl consid perform nu studi
yield sensit specif hypothet test could use screen
asymptomat individu preval mean
subject popul studi nu panel
appli popul would correctli identifi diseas individu
incorrectli implic fals posit subject
graphic perform diagnost visual receiv oper
characterist roc curv plot sensit vertic axi specif
horizont axi exhibit ideal diagnost sensit
specif translat auc area curv shown
panel four nu qs studi summar exhibit achiev impress auc
could improv incorpor subject age inform illustr
purpos non-proprietari test serum level inferior diagnost yield
anoth common metric diagnost perform posit predict valu ppv
ppv indic test effici identifi diseas individu import
consider measur healthcar util cost associ
diagnost ppv measur likelihood individu test posit test
actual diseas mathemat ppv posit posit fals
posit use exampl ppv studi panel would
due larg number fals posit popul howev
assum nu panel sensit high-risk adenoma hra
preval hra approxim popul ppv dramat
increas
size competit
asymptomat screen studi perform nu panel
demonstr sensit specif assum perform hold
larger valid studi begin compar nu q-base diagnost
approv non-invas screen method see exhibit given studi
result would expect perform nu q-base panel lower fit-
base method potenti better approv blood-bas diagnost
epi procolon blood-bas diagnost manufactur epigenom ag
approv fda patient refus recommend screen includ
colonoscopi epi procolon ctdna test detect methyl dna
gene valid studi epi procolon yield modest sensit
specif believ approv product highlight low regulatori
bar place blood-bas diagnost
importantli note volitionrx work date nu investig panel
three four nu qs believ addit nu qs may ad improv
perform compani guid final panel nu qs use
screen valid studi could includ five six differ assay includ mix
nu qs non-proprietari biomark assay
exhibit hypothet comparison nu diagnost rel competitor
volitionrx test differ panel nu qs without non-proprietari
assay serum test sampl goal lock final
product panel volit plan use panel valid studi
sponsor nation cancer institut earli detect research network
edrn/nci could use support pma applic us regulatori approv
previous mention believ fda set low bar approv base
preced epi procolon
test sens sensit hra specificityppv ppv hra preval preval per engl vnrx outperform
although includ nu qs panel could improv perform believ
nu screen could potenti commerci success even perform
level seen studi believ success commerci diagnost us
depend accept uspstf list recommend screen
approach epi procolon includ latest recommend
statement epigenom activ pursu inclus next guidanc
uspstf decis could set standard nu q-base screen meet beat
believ uspstf signal open test method reduc
screen non-compli acknowledg one-size-fits-al approach
histor uspstf base screen recommend healthcar
econom diagnost rel low specif would fare wors due
larg rate fals posit result unnecessari cost incur follow-up
colonoscopi instead uspstf decis primarili base benefit-to-risk
ratio patient
base estim benefit risk diagnost includ uspstf
recent recommend statement believ nu q-base screen
sensit respect sensit cologuard would save
diagnost would carri almost risk patient believ could still maintain
favor benefit-to-risk ratio even specif fals posit rate
sensit line assum nu q-base screen use would
recommend yearli improv odd success detect submit
invas colonoscopi fals posit subject would like self-motiv tri
altern diagnost like cologuard superior specif
adapt jama jun
tailor perform market need
result complet studi nu q-base diagnost suggest test
modifi trade specif sensit vice versa adjust algorithm use
process raw elisa data practic mean test perform
tailor meet need specif market exampl specif may
import rel sensit countri insuffici colonoscopi capac
situat risk colonoscopi consid high believ nu
diagnost could optim maximum specif regul express concern
high rate fals posit volitionrx could adapt modifi diagnost
respons futur guidanc uspstf and/or european counterpart
meet need market
market opportun non-compli
believ nu q-base screen product could market patient
non-compli recommend screen approach colonoscopi
us eu believ nu q-base screen could address sizeabl non-
compliant popul exampl use censu estim us
non-compli rate amongst averag risk adult age would
equat approxim candid potenti elig nu q-base screen bold
effort increas screen complianc propos includ
initi spearhead nation colorect cancer roundtabl
coordin american cancer societi cdc even lofti goal met
approxim subject us would remain non-compli estim see
exhibit estim screen non-compli popul us
cologuard like improv screen rate us test never-before-
screen subject account roughli total test perform suggest
cologuard also usurp market share colonoscopi believ
cologuard track approxim test consensu expect
sale correspond approxim test view leav ampl room
nu q-base screen non-compli popul
market model nu screen product
believ nu screen could approv us via pma front-lin
screen option non-compli subject base result
sampl valid studi coordin nci earli detect network eu
anticip nu screen could ce mark begin commerci
base result sampl valid studi conduct denmark
believ nu could achiev favor reimburs rate us eu
base preced set epi procolon cologuard us center
medicar medicaid servic award cologuard reimburs
recent propos reimburs epi procolon list price
us eu valid perform sensit
specif believ nu q-base screen would offer healthcar econom benefit
use estim cost colorect cancer death us healthcar system
model estim peak us sale correspond approxim
estim address non-compli popul risk-adjust sale
basi year valuat eu estim peak sale
correspond approxim address non-compli popul
risk-adjust sale approxim detail market model nu
screen shown exhibit
exhibit market model nu colorect cancer front-lin screen non-compli subject
valuat volitionrx base potenti diagnost improv
colorect screen non-compli subject believ compani could tap
much larger market valid work demonstr test perform level
similar cologuard scenario see exhibit believ nu could
recommend uspstf standard front-lin option compet directli
other compar purpos current market capit
exhibit perform nu diagnost upsid scenario
nu screen sale elig popul age risk elig popul assum high risk normal risk popul assum non-compli nu size market screen nu adjust sale volit screen sale elig popul age risk elig popul assum high risk normal risk popul assum non-compli nu size market screen nu adjust sale volit specif compar specif compar cologuardupsid case volitionrx limit
nu triag may address colonoscopi burden
select eu countri volit explor use nu q-base product triag
method combin improv sensit reduc needless
colonoscopi previous mention eu countri mandat nationwid
screen program reli test identifi subject receiv
colonoscopy-bas evalu countri includ denmark
netherland insuffici capac scope fit-posit subject
rais cut-off level test effort improv specif reflex
reduc sensit minim number subject subsequ fall
crack triag strategi could implement patient posit
result cut-off level requir automat colonoscopi referr could
offer nu triag test
appli triag set nu may reduc colonoscopi burden
minim number patient miss chang cutoff volit
conduct initi research concept use data danish nation screen
program show nu triag reduc unnecessari colonoscopi
success catch addit miss early-stag
market model nu triag
believ nu could receiv ce mark eu late could util
triag set begin earli model assum nu triag
success implement nationwid fit-screen program
denmark sweden netherland use estim number subject
affect rais cut-off per scand gastroenterol jun
believ nu triag could use approxim subject
price per nu test discount rel estim price
frontlin screen assum robust penetr popul
estim nu triag could gener peak sale risk-adjust
sale approxim basi year valuat see exhibit
exhibit market model nu triag
nu triag select elig popul age screen elig patient assum screen complianc posit assum posit rate triag elig assum posit nu size market sale adjust sale volit vnrx outperform
volit develop extens ip estat protect innov nu test
compani patent famili cover diagnost five patent grant
unit state four patent grant european union addit volit
patent applic name subsidiari pend unit state
patent applic european union per compani march form
issu patent provid broad coverag least
volit approxim cash cash equival market secur
end believ compani suffici resourc fund oper
earli includ singl dilut financ model could
sustain oper compani potenti becom cash flow posit
believ nu screen test could launch eu us
gener peak non risk-adjust revu europ us
addit expect compani nu triag product launch select eu
countri provid modest revenu stream compani peak
sale addit model modest royalti stream associ sale research-
kit commerci partner activ motif start ramp
approxim approxim anticip total risk-adjust
revenu ramp basi year valuat
introduc estim ramp
estim expens ramp
molecular diagnost compani assum sale market becom
domin oper expens volitionrx introduc estim
ramp assum cog volit nu product
believ in-lin diagnost compani
net incom ep
project net loss per share ramp net
incom per share expect see increas cash burn
associ increas sg spend volit transit
commercial-stag compani
cameron experienc entrepreneuri execut expertis biotechnolog
compani extens experi manag structur strateg
plan start-up compani held posit includ chief execut offic
chief offic non-execut director public privat enterpris
cameron educ univers western australia receiv bachelor
commerc
david year financi manag experi prior volit octo
telemat david held posit vice presid excorp medic inc early-stag
compani chief offic growhow ltd vice presid europ financ
monster world-wide inc david manag oversaw account financ tax
treasuri financi plan analysi busi david certifi charter
account hold mba warwick busi school
jake experienc scientist expertis research develop
manag earli stage biotechn compani includ manufactur
biotechnolog product establish manufactur oper jake receiv
bsc biolog chemistri phd physic chemistri king colleg
london addit receiv chemic patholog st thoma hospit
medic school mba imperi colleg manag school
jason expertis clinic medicin laboratori diagnost educ
hardin-simmon univers biochemistri graduat summa cum laud also
receiv holland medal honor receiv doctor medicin
univers texa medic school houston affili md anderson cancer center
jason strong ground medicin specif diagnost
sec file oppenheim co research
figur thousand except per share revenu nu us sale european sale good sold expens research develop gener administr sale oper loss incom incom expens interest loss incom incom incom loss comprehens loss gain foreign currenc translat comprehens incom loss per share share outstand co inc mark breidenbach volitionrx limit
sec file oppenheim co research
figur cash current current equip asset director fee portion long term portion capit leas grant portion grant current leas equitycommon paid-in comprehens stockhold liabil stockhold co inc mark breidenbach vnrx outperform
price compani mention report
becton dickinson compani bdx-nyse cover
